Stuttgart - Delayed Quote EUR

2SX.SG,0P0001JZ9A,0 (2SX.SG)

4.4800

+0.3000

(+7.18%)

As of July 23 at 10:00:00 PM GMT+2. Market Open.

scPharmaceuticals Provides Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Results

Preliminary unaudited fourth quarter 2024 net revenue expected to be approximately $12 million to $12.3 million, representing 99% growth over Q4 2023 at the mid-point of the range Fourth quarter 2024 Gross-to-net (GTN) discount expected to be in the range of 18% to 19% Preliminary unaudited full year 2024 net revenue expected to be approximately $36.2 million to $36.5 million, compared to $13.6 million for full year 2023 BURLINGTON, Mass., Jan. 10, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc.

GlobeNewswire 5 hours ago

SCPH
scPharmaceuticals Inc.'s (NASDAQ:SCPH) Shift From Loss To Profit

With the business potentially at an important milestone, we thought we'd take a closer look at scPharmaceuticals Inc.'s...

Simply Wall St. 10 days ago

SCPH
Earnings Update: scPharmaceuticals Inc. (NASDAQ:SCPH) Just Reported And Analysts Are Trimming Their Forecasts

As you might know, scPharmaceuticals Inc. ( NASDAQ:SCPH ) last week released its latest third-quarter, and things did...

Simply Wall St. last month

SCPH
scPharmaceuticals Third Quarter 2024 Earnings: Misses Expectations

scPharmaceuticals ( NASDAQ:SCPH ) Third Quarter 2024 Results Key Financial Results Revenue: US$10.0m (up 164% from 3Q...

Simply Wall St. last month

SCPH
scPharmaceuticals Inc. Reports Third Quarter 2024 Financial Results and Provides Business Update

Generated 3Q 2024 net FUROSCIX® revenue of $10.0 million, up 164% from Q3 2023 Received approval of label expansion to include New York Heart Association (NYHA) Class IV Patients Announced positive pharmacokinetic/pharmacodynamic (PK/PD) data on Autoinjector program Completed $125 million transformative financing in a combination of debt and equity that is anticipated to fund the Company through expected profitability Company to host investor conference call and webcast today, Wednesday, Novembe

GlobeNewswire last month

SCPH
scPharmaceuticals to Announce Third Quarter 2024 Financial Results on Wednesday, November 13, 2024

Management to host conference call and webcast, after-market on November 13, 2024, at 4:30 p.m. ETBURLINGTON, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, today announced that scPharmaceuticals management will host a conference call and audio webcast at 4:30 p.m. ET on Wednesday, November 13, 2024, to discuss the financial results for the third quar

GlobeNewswire 2 months ago

SCPH
scPharmaceuticals to Host Key Opinion Leader (KOL) Webinar on October 22, 2024

Webinar to focus on a nephrologist’s perspective on the use of FUROSCIX for fluid overload in heart failure and potential use in chronic kidney diseaseBURLINGTON, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that it will host a KOL webinar focused on

GlobeNewswire 2 months ago

SCPH
Investors in scPharmaceuticals (NASDAQ:SCPH) have unfortunately lost 23% over the last year

It is doubtless a positive to see that the scPharmaceuticals Inc. ( NASDAQ:SCPH ) share price has gained some 38% in...

Simply Wall St. 3 months ago

SCPH
scPharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

BURLINGTON, Mass., Sept. 04, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that John Tucker, President & Chief Executive Officer, will present at the H.C. Wainwright 26th Annual Global Investment Conference on Wednesday, September 11 at 10:00AM ET. Mr. Tucker will als

GlobeNewswire 4 months ago

SCPH
After losing 35% in the past year, scPharmaceuticals Inc. (NASDAQ:SCPH) institutional owners must be relieved by the recent gain

Key Insights Significantly high institutional ownership implies scPharmaceuticals' stock price is sensitive to their...

Simply Wall St. 4 months ago

SCPH
scPharmaceuticals Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update

Generated 2Q 2024 net FUROSCIX® revenue of $8.1 million, up 33% sequentially from Q1 Completed financing that extends our cash runway through expected profitability Advanced multiple FUROSCIX growth initiatives including label expansion for heart failure, sNDA submission for CKD, and positive topline pivotal PK data for our Autoinjector Company to host investor conference call and webcast today, Wednesday, August 14th, at 4:30pm ET BURLINGTON, Mass., Aug. 14, 2024 (GLOBE NEWSWIRE) -- scPharmaceu

GlobeNewswire 4 months ago

SCPH
scPharmaceuticals Announces Pricing of $50.0 Million Public Offering

BURLINGTON, Mass., Aug. 12, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced the pricing of an underwritten public offering of 12,000,000 shares of its common stock at a public offering price of $4.00 per share and, to select investors, in lieu of common stock, pre-funde

GlobeNewswire 4 months ago

SCPH
scPharmaceuticals Announces Non-Dilutive Financings Totaling Up to $125 Million with Perceptive Advisors

scPharmaceuticals received $75 million through a combination of debt and royalty financings at close, with access to an additional $50 million The term loan refinances existing debt principal; lowers coupon, extends interest-only period for four additional years, and lowers minimum cash requirement to $5 million BURLINGTON, Mass., Aug. 12, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the “Company”), a pharmaceutical company focused on developing and commercializing products th

GlobeNewswire 4 months ago

SCPH
scPharmaceuticals Announces FDA Approval of Supplemental New Drug Application Expanding the FUROSCIX Indication in Heart Failure

FUROSCIX is now indicated for the treatment of congestion due to fluid overload in adult patients with chronic heart failure, regardless of New York Heart Association (NYHA) functional class Indication expansion allows for the use of FUROSCIX in NYHA Class IV chronic heart failure patients BURLINGTON, Mass., Aug. 12, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the “Company”), a pharmaceutical company focused on developing and commercializing products that have the potential t

GlobeNewswire 4 months ago

SCPH
scPharmaceuticals Announces Positive Topline Study Results for SCP-111 (Furosemide 80 mg/1 mL) Autoinjector

SCP-111 Autoinjector achieved primary pharmacokinetic and secondary pharmacodynamic endpoints The autoinjector is being developed to deliver a subcutaneous injection of furosemide as an alternative option to the FDA approved FUROSCIX on-body infusor presentation Company targeting Supplemental New Drug Application (sNDA) submission to the FDA by year-end 2024 BURLINGTON, Mass., Aug. 12, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the “Company”), a pharmaceutical company focuse

GlobeNewswire 4 months ago

SCPH
scPharmaceuticals Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants

BURLINGTON, Mass., Aug. 12, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the “Company”), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced a proposed underwritten public offering of shares (“Shares”) of its common stock or, in lieu of Shares, pre-funded warrants (the “Pre-Funded Warrants”) to purchase Shares (the “O

GlobeNewswire 4 months ago

SCPH
scPharmaceuticals to Announce Second Quarter 2024 Financial Results on Wednesday, August 14, 2024

Management to host conference call and webcast at 4:30 p.m. ETBURLINGTON, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that scPharmaceuticals management will host a conference call and audio webcast at 4:30 p.m. ET on Wednesday, August 14, 2024, to di

GlobeNewswire 4 months ago

SCPH
scPharmaceuticals Announces Filing Acceptance of Supplemental New Drug Application (sNDA) Seeking to Expand FUROSCIX Indication to Include Chronic Kidney Disease

FDA assigns Prescription Drug User Fee Act (PDUFA) target action date of March 6, 2025 BURLINGTON, Mass., July 25, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the “Company”), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company’s Supp

GlobeNewswire 5 months ago

SCPH
When Will scPharmaceuticals Inc. (NASDAQ:SCPH) Breakeven?

We feel now is a pretty good time to analyse scPharmaceuticals Inc.'s ( NASDAQ:SCPH ) business as it appears the...

Simply Wall St. 5 months ago

SCPH
Increases to scPharmaceuticals Inc.'s (NASDAQ:SCPH) CEO Compensation Might Cool off for now

Key Insights scPharmaceuticals' Annual General Meeting to take place on 11th of June Total pay for CEO John Tucker...

Simply Wall St. 7 months ago

SCPH

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

2SX.SG,0P0001JZ9A,0 (2SX.SG)

scPharmaceuticals Provides Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Results

scPharmaceuticals Inc.'s (NASDAQ:SCPH) Shift From Loss To Profit

Earnings Update: scPharmaceuticals Inc. (NASDAQ:SCPH) Just Reported And Analysts Are Trimming Their Forecasts

scPharmaceuticals Third Quarter 2024 Earnings: Misses Expectations

scPharmaceuticals Inc. Reports Third Quarter 2024 Financial Results and Provides Business Update

scPharmaceuticals to Announce Third Quarter 2024 Financial Results on Wednesday, November 13, 2024

scPharmaceuticals to Host Key Opinion Leader (KOL) Webinar on October 22, 2024

Investors in scPharmaceuticals (NASDAQ:SCPH) have unfortunately lost 23% over the last year

scPharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

After losing 35% in the past year, scPharmaceuticals Inc. (NASDAQ:SCPH) institutional owners must be relieved by the recent gain

scPharmaceuticals Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update

scPharmaceuticals Announces Pricing of $50.0 Million Public Offering

scPharmaceuticals Announces Non-Dilutive Financings Totaling Up to $125 Million with Perceptive Advisors

scPharmaceuticals Announces FDA Approval of Supplemental New Drug Application Expanding the FUROSCIX Indication in Heart Failure

scPharmaceuticals Announces Positive Topline Study Results for SCP-111 (Furosemide 80 mg/1 mL) Autoinjector

scPharmaceuticals Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants

scPharmaceuticals to Announce Second Quarter 2024 Financial Results on Wednesday, August 14, 2024

scPharmaceuticals Announces Filing Acceptance of Supplemental New Drug Application (sNDA) Seeking to Expand FUROSCIX Indication to Include Chronic Kidney Disease

When Will scPharmaceuticals Inc. (NASDAQ:SCPH) Breakeven?

Increases to scPharmaceuticals Inc.'s (NASDAQ:SCPH) CEO Compensation Might Cool off for now